bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 13.55M |
| Revenue (ttm) | 321,489 |
| Net Income (ttm) | -7.24M |
| Shares Out | 9.22M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,670 |
| Open | 1.60 |
| Previous Close | 1.64 |
| Day's Range | 1.47 - 1.60 |
| 52-Week Range | 0.96 - 3.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2023 |
About BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]
Financial Performance
Financial StatementsNews
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024
SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the appointment of Dallas Coleman as National Director of Sales.
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.
bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, ann...
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports second quarter 2023 financial results and provides business update.
AMA Issues CPT Code for bioAffinity Technologies' CyPath® Lung Test for Early-Stage Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AMA--The AMA has issued a CPT code specifically for bioAffinity Technologies' CyPath® Lung noninvasive test for early-stage lung cancer.
bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents research at UMass 5th annual RNA Therapeutics Symposium June 21-23.
bioAffinity Technologies Presents Research Findings at CYTO 2023
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents research findings at CYTO 2023.
bioAffinity Technologies Reports First Quarter 2023 Financial Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies releases first quarter 2023 financial results and reports progress on CyPath Lung diagnostic.
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today.
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies will present at the invitation-only Cleveland Clinic annual symposium on advances in early-stage lung cancer detection.
bioAffinity Technologies to Ring Nasdaq Closing Bell Today
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies rings the Nasdaq Stock Market closing bell this afternoon to commemorate the Company's 2022 initial public offering (IPO).
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases ...
bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #CyPathLung--bioAffinity's scientific paper on proprietary compensation beads used in the CyPath® Lung test is published in peer-reviewed journal.
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2...
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broa...
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and ...
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent a...
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) Click H...
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lu...